TY - JOUR
T1 - Persistent somatic symptoms are key to individual illness perception at one year after COVID-19 in a cross-sectional analysis of a prospective cohort study
AU - Hüfner, Katharina
AU - Tymoszuk, Piotr
AU - Sahanic, Sabina
AU - Luger, Anna
AU - Boehm, Anna
AU - Pizzini, Alex
AU - Schwabl, Christoph
AU - Koppelstätter, Sabine
AU - Kurz, Katharina
AU - Asshoff, Malte
AU - Mosheimer-Feistritzer, Birgit
AU - Pfeifer, Bernhard
AU - Rass, Verena
AU - Schroll, Andrea
AU - Iglseder, Sarah
AU - Egger, Alexander
AU - Wöll, Ewald
AU - Weiss, Günter
AU - Helbok, Raimund
AU - Widmann, Gerlig
AU - Sonnweber, Thomas
AU - Tancevski, Ivan
AU - Sperner-Unterweger, Barbara
AU - Löffler-Ragg, Judith
N1 - Copyright © 2023. Published by Elsevier Inc.
PY - 2023/6
Y1 - 2023/6
N2 - OBJECTIVE: Subjective illness perception (IP) can differ from physician's clinical assessment results. Herein, we explored patient's IP during coronavirus disease 2019 (COVID-19) recovery.METHODS: Participants of the prospective observation CovILD study (ClinicalTrials.gov: NCT04416100) with persistent somatic symptoms or cardiopulmonary findings one year after COVID-19 were analyzed (n = 74). Explanatory variables included demographic and comorbidity, COVID-19 course and one-year follow-up data of persistent somatic symptoms, physical performance, lung function testing, chest computed tomography and trans-thoracic echocardiography. Factors affecting IP (Brief Illness Perception Questionnaire) one year after COVID-19 were identified by regularized modeling and unsupervised clustering.RESULTS: In modeling, 33% of overall IP variance (R2) was attributed to fatigue intensity, reduced physical performance and persistent somatic symptom count. Overall IP was largely independent of lung and heart findings revealed by imaging and function testing. In clustering, persistent somatic symptom count (Kruskal-Wallis test: η2 = 0.31, p < .001), fatigue (η2 = 0.34, p < .001), diminished physical performance (χ2 test, Cramer V effect size statistic: V = 0.51, p < .001), dyspnea (V = 0.37, p = .006), hair loss (V = 0.57, p < .001) and sleep problems (V = 0.36, p = .008) were strongly associated with the concern, emotional representation, complaints, disease timeline and consequences IP dimensions.CONCLUSION: Persistent somatic symptoms rather than abnormalities in cardiopulmonary testing influence IP one year after COVID-19. Modifying IP represents a promising innovative approach to treatment of post-COVID-19 condition. Besides COVID-19 severity, individual IP should guide rehabilitation and psychological therapy decisions.
AB - OBJECTIVE: Subjective illness perception (IP) can differ from physician's clinical assessment results. Herein, we explored patient's IP during coronavirus disease 2019 (COVID-19) recovery.METHODS: Participants of the prospective observation CovILD study (ClinicalTrials.gov: NCT04416100) with persistent somatic symptoms or cardiopulmonary findings one year after COVID-19 were analyzed (n = 74). Explanatory variables included demographic and comorbidity, COVID-19 course and one-year follow-up data of persistent somatic symptoms, physical performance, lung function testing, chest computed tomography and trans-thoracic echocardiography. Factors affecting IP (Brief Illness Perception Questionnaire) one year after COVID-19 were identified by regularized modeling and unsupervised clustering.RESULTS: In modeling, 33% of overall IP variance (R2) was attributed to fatigue intensity, reduced physical performance and persistent somatic symptom count. Overall IP was largely independent of lung and heart findings revealed by imaging and function testing. In clustering, persistent somatic symptom count (Kruskal-Wallis test: η2 = 0.31, p < .001), fatigue (η2 = 0.34, p < .001), diminished physical performance (χ2 test, Cramer V effect size statistic: V = 0.51, p < .001), dyspnea (V = 0.37, p = .006), hair loss (V = 0.57, p < .001) and sleep problems (V = 0.36, p = .008) were strongly associated with the concern, emotional representation, complaints, disease timeline and consequences IP dimensions.CONCLUSION: Persistent somatic symptoms rather than abnormalities in cardiopulmonary testing influence IP one year after COVID-19. Modifying IP represents a promising innovative approach to treatment of post-COVID-19 condition. Besides COVID-19 severity, individual IP should guide rehabilitation and psychological therapy decisions.
KW - Humans
KW - COVID-19
KW - Prospective Studies
KW - Cross-Sectional Studies
KW - Medically Unexplained Symptoms
KW - Perception
KW - Fatigue/etiology
UR - https://www.scopus.com/pages/publications/85150786839
U2 - 10.1016/j.jpsychores.2023.111234
DO - 10.1016/j.jpsychores.2023.111234
M3 - Article
C2 - 36965396
SN - 0022-3999
VL - 169
JO - Journal of psychosomatic research
JF - Journal of psychosomatic research
M1 - 111234
ER -